Author(s): Yiang, GT (Yiang, Giou-Teng); Harn, HJ (Harn, Horng-Jyh); Yu, YL (Yu, Yung- Luen); Hu, SC (Hu, Sheng-Chuan); Hung, YT (Hung, Yu-Ting); Hsieh, CJ (Hsieh, Chia-Jung);
Lin, SZ (Lin, Shinn-Zong); Wei, CW (Wei, Chyou-Wei)
Title: Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
Source: JOURNAL OF BIOMEDICAL SCIENCE, 16: Art. No. 47 MAY 7 2009 Language: English
Document Type: Article
KeyWords Plus: RECOMBINANT ADENOASSOCIATED VIRUS; DIRECTED GENE- THERAPY; CANCER A549 CELLS; IN-VIVO; EFFICIENT TRANSDUCTION; TRANSGENE EXPRESSION; IMMUNOGENE THERAPY; IMMUNE-RESPONSE; DENDRITIC CELLS;
PROTEIN-KINASE
Abstract: Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.
Addresses: [Lin, Shinn-Zong] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan;
[Yiang, Giou-Teng; Hu, Sheng-Chuan] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Yiang, Giou-Teng; Hu, Sheng-Chuan] Tzu Chi Gen Hosp, Dept Emergency Med, Hualien, Taiwan;
[Harn, Horng-Jyh] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Yu, Yung-Luen]
China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Yu, Yung-Luen] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Yu, Yung-Luen] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Hung, Yu-Ting; Hsieh, Chia-Jung; Wei, Chyou-Wei] Hung Kuang Univ, Coll Med & Nursing, Inst Biomed Nutr, Taichung, Taiwan
Reprint Address: Lin, SZ, China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan.
E-mail Address: [email protected]; [email protected];
[email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected] Cited References: ARMITAGE RJ, 1995, J IMMUNOL, V154, P483.
AURICCHIO A, 2001, HUM GENE THER, V12, P71.
BAMFORD RN, 1996, P NATL ACAD SCI USA, V93, P2897.
BURTON EA, 2002, DNA CELL BIOL, V21, P915.
CARSON WE, 1994, J EXP MED, V180, P1395.
CHAPOVAL AI, 1998, J IMMUNOL, V161, P6977.
CHEN YL, 2006, BIOCHEM PHARMACOL, V72, P308, DOI 10.1016/j.bcp.2006.04.031.
CHEN YL, 2007, J PHARMACOL EXP THER, V323, P746, DOI 10.1124/jpet.107.126193.
CROCE M, 2005, CLIN CANCER RES, V11, P735.
DONG JY, 1996, HUM GENE THER, V7, P2101.
EVANS R, 1997, CELL IMMUNOL, V179, P66.
FISHER KJ, 1997, NAT MED, V3, P306.
FLANNERY JG, 1997, P NATL ACAD SCI USA, V94, P6916.
GAO GP, 2000, HUM GENE THER, V11, P2079.
GHOSH SS, 2006, APPL BIOCHEM BIOTECH, V133, P9.
GIRI JG, 1994, EMBO J, V13, P2822.
GRABSTEIN KH, 1994, SCIENCE, V264, P965.
HIRATA RK, 2000, J VIROL, V74, P4612.
JENNINGS K, 2005, MOL THER, V11, P600, DOI 10.1016/j.ymthe.2004.10.020.
JIANG YF, 2001, CANCER RES, V61, P2365.
JOOSS K, 1998, J VIROL, V72, P4212.
KLEBANOFF CA, 2004, P NATL ACAD SCI USA, V101, P1969, DOI 10.1073/pnas.0307298101.
LOEWEN N, 2005, ADV BIOCHEM ENG BIOT, V99, P169, DOI 10.1007/10_007.
MCCARTY DM, 2001, GENE THER, V8, P1248.
MCDERMOTT DF, 2006, SEMIN ONCOL, V33, P583, DOI 10.1053/j.seminoncol.2006.06.004.
ORENGO AM, 2003, J IMMUNOL, V171, P569.
ROSENBERG SA, 1985, J EXP MED, V161, P1169.
RUBINSTEIN MP, 2002, J IMMUNOL, V169, P4928.
SASAHIRA T, 2005, J EXP CLIN CANC RES, V24, P69.
SAWCHUK SJ, 1996, HUM GENE THER, V7, P499.
SNYDER RO, 2002, CURR OPIN BIOTECH, V13, P418.
SONG SH, 2001, P NATL ACAD SCI USA, V98, P4084.
SUZUKI K, 2001, J LEUKOCYTE BIOL, V69, P531.
WAGNER JA, 1998, HUM GENE THER, V9, P889.
WALDMANN TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901.
WANG LL, 2005, BLOOD, V105, P3079, DOI 10.1182/blood-2004-10-3867.
WANG Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133.
YOSHIMUTA T, 2004, KURUME MED J, V51, P225.
ZOLOTUKHIN S, 1999, GENE THER, V6, P973.
Cited Reference Count: 39 Times Cited: 1
Publisher: BIOMED CENTRAL LTD
Publisher Address: CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
ISSN: 1021-7770 Article Number: 47
DOI: 10.1186/1423-0127-16-47
29-char Source Abbrev.: J BIOMED SCI ISO Source Abbrev.: J. Biomed. Sci.
Source Item Page Count: 8
Subject Category: Medicine, Research & Experimental ISI Document Delivery No.: 460EW
